Myeloproliferative neoplasms trials in France

In France 40 Also abroad 210

40 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 12 November 2026. Ask the study team whether a trial fits you.

No phaseTaking people
Clonal Architecture of ASXL1-mutated Myelofibrosis
Where
Angers, Brest, Cholet, Créteil, Marseille, Nantes, Paris, Pessac, Pierre-Bénite, Quimper, Tours, Vannes
Age
18 years and over
People
50
Run by
University Hospital, Angers
See details and how to joinNCT05710211
No phaseTaking people
Interest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syndromes (CALRSUIVI)
Where
Angers, Bordeaux, Brest, Cholet, Le Mans, Morlaix, Paris, Poitiers, Quimper, Tours
Age
18 years and over
People
260
Run by
University Hospital, Angers
See details and how to joinNCT04942080
No phaseTaking people
Identification of Factors Associated With Treatment Response in Patients With Polycythemia Vera, Essential Thrombocythemia, and Pre-myelofibrosis.
Where
Angers, Brest, Nantes, Poitiers, Rennes, Tours
Age
18 years and over
People
120
Run by
University Hospital, Angers
See details and how to joinNCT05440838
Phase 2Taking people
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
Where
Angers, Bordeaux, Nîmes, Paris, Pierre-Bénite, Saint-Priest-en-Jarez, Tours
Age
18 years and over
People
58 worldwide
Run by
Karyopharm Therapeutics Inc
See details and how to joinNCT05980806
Phase 2Taking people
A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis
Where
Nimes Cedex 9, Pierre-Bénite
Age
18 years and over
People
135 worldwide
Run by
Takeda
See details and how to joinNCT05037760 · EU 2023-507468-38-00
No phaseNot yet taking people in France
Potential Biological and Physiological Determinants for Exercice in Patients With Polycythemia Vera
Where
Lyon
Age
18 years to 70 years
People
54
Run by
Hospices Civils de Lyon
See details and how to joinNCT07341048
No phaseTaking people
Prognostic Value of NETosis Markers for Thrombosis During Myeloproliferative Neoplasms (AVATARE)
Where
Angers, Bayonne, Bordeaux, Brest, Créteil, La Roche-sur-Yon, Le Kremlin-Bicêtre, Libourne, Limoges, Morlaix, Nantes, Paris, Roubaix
Age
18 years and over
People
300
Run by
University Hospital, Bordeaux
See details and how to joinNCT07119970
Phase 3Taking people
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
Where
Amiens, Angers, Lille, Lyon, Nantes, Nice, Nîmes, Paris, Pessac, Poitiers, Strasbourg, Toulouse, Tours
Age
18 years and over
People
600 worldwide
Run by
Kartos Therapeutics, Inc.
See details and how to joinNCT06479135
No phaseTaking people
Impact of Epigenetic Age on Clinic-biological Presentation and Prognosis in Myeloproliferative Neoplasms Epigenetic Age in Myeloproliferative Neoplasms (EpiC)
Where
Bordeaux
Age
18 years and over
People
120
Run by
University Hospital, Bordeaux
See details and how to joinNCT06022328
Phase 2/3Taking people
Apixaban/rivaroxaban Versus Aspirin for primary prevention of thrombo-embolic complications in JAK2V617F-positive myeloproliferative neoplasms
Where
Angers, Argenteuil Cedex, Avignon, Bayonne, Béziers, Brest, Cesson Sevigne, Clermont-Ferrand, Créteil, Grenoble Cedex 9, La Roche Sur Yon Cedex 9, Le Chesnay Rocquencourt, Le Havre Cedex, Le Mans Cedex 9, Libourne, Limoges Cedex 1, Lyon, Marseille Cedex 05, Mont-De-Marsan Cedex, Montpellier Cedex 5, Morlaix, Nantes, ORLEANS, Paris, Périgueux, Perpignan Cedex, Pessac, Pringy Cedex, Quimper Cedex, Rennes, Rochefort Cedex, Roubaix, Rouen Cedex, Saint-Denis, Saint-Pierre Cedex, Saint-Priest-en-Jarez, Strasbourg, Tours, Vandoeuvre lès Nancy, Vannes, Villejuif Cedex, Villeurbanne
Age
18 years and over
People
1,008
Run by
Centre Hospitalier Regional Et Universitaire De Brest
See details and how to join2024-515362-13-00 · EU 2024-515362-13-00
No phaseTaking people
Determination of the Clonality Profile in Myeloproliferative Neoplasms and Association With the Thrombotic Complications (CLOJAK)
Where
Angers, Bayonne, Bordeaux, Brest, Dax, Libourne, Mont-de-Marsan, Pessac
Age
18 years and over
People
120
Run by
University Hospital, Bordeaux
See details and how to joinNCT05839717
No phaseTaking people
Children, Adolescents and Young Adults with Myeloproliferative Neoplasia: Study of Clinico-biological Characteristics and Complications (VYP)
Where
Brest
Age
0 years to 30 years
People
200
Run by
University Hospital, Brest
See details and how to joinNCT06715267
No phaseTaking people
Exploring the Impact of Monocytes in Myeloproliferative Neoplasia (EMYNEM)
Where
Brest
Age
18 years and over
People
10
Run by
University Hospital, Brest
See details and how to joinNCT06462664
No phaseTaking people
The Patient Cohort of the National Center for Precision Medicine in Leukemia
Where
Bobigny, Paris
People
3,000
Run by
Assistance Publique - Hôpitaux de Paris
See details and how to joinNCT05326919
Phase 1/2Taking people
Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib
Where
Angers, Marseille, Nice, Paris, Pierre-Bénite
Age
18 years and over
People
70 worldwide
Run by
Telios Pharma, Inc.
See details and how to joinNCT05280509